Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores

Current Opinion in Nephrology and Hypertension
Bauke SchievinkHiddo J Lambers Heerspink

Abstract

There is increased interest in developing surrogate endpoints for clinical trials of chronic kidney disease progression, as the established clinically meaningful endpoint end-stage renal disease requires large and lengthy trials to assess drug efficacy. We describe recent developments in the search for novel surrogate endpoints. Declines in estimated glomerular filtration rate (eGFR) of 30% or 40% and albuminuria have been proposed as surrogates for end-stage renal disease. However, changes in eGFR or albuminuria may not be valid under all circumstances as drugs always have effects on multiple renal risk markers. Changes in each of these other 'off-target' risk markers can alter renal risk (either beneficially or adversely), and can thereby confound the relationship between surrogates that are based on single risk markers and renal outcome. Risk algorithms that integrate the short-term drug effects on multiple risk markers to predict drug effects on hard renal outcomes may therefore be more accurate. The validity of these risk algorithms is currently investigated. Given that drugs affect multiple renal risk markers, risk scores that integrate these effects are a promising alternative to using eGFR decline or albuminuria. Proper...Continue Reading

References

Mar 10, 2001·Clinical Pharmacology and Therapeutics·UNKNOWN Biomarkers Definitions Working Group.
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Feb 28, 2003·Journal of Health Economics·Joseph A DiMasiHenry G Grabowski
Feb 3, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Robert C AtkinsEdmund J Lewis
Dec 8, 2005·Clinical Chemistry·Gary L MyersUNKNOWN National Kidney Disease Education Program Laboratory Working Group
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Dec 19, 2008·Journal of the American Society of Nephrology : JASN·Elsbeth C WitteRonald Gansevoort
Feb 5, 2010·Clinical Pharmacology and Therapeutics·J A DiMasiA Wilson
Feb 20, 2010·Journal of the American Society of Nephrology : JASN·Johannes F E MannUNKNOWN ASCEND Study Group
Sep 8, 2010·The New England Journal of Medicine·W Philip T JamesUNKNOWN SCOUT Investigators
Sep 3, 2011·Current Opinion in Nephrology and Hypertension·William MullenUNKNOWN EuroKUP COST action
Nov 6, 2012·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN ALTITUDE Investigators
Mar 1, 2013·Kidney International·Flavio GaspariUNKNOWN GFR Study Investigators
Mar 8, 2013·European Journal of Preventive Cardiology·P A SminkH J Lambers Heerspink
Nov 12, 2013·The New England Journal of Medicine·Linda F FriedUNKNOWN VA NEPHRON-D Investigators
Apr 25, 2014·Kidney International·Sara S RoscioniDick de Zeeuw
Jun 4, 2014·JAMA : the Journal of the American Medical Association·Josef CoreshAndrew S Levey
Jun 28, 2014·Journal of the American Society of Nephrology : JASN·Juan F Navarro-GonzálezJavier García
Sep 10, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jessica M SontropAmit X Garg
Nov 16, 2014·Nature Reviews. Drug Discovery·Hiddo J Lambers HeerspinkDick de Zeeuw
Dec 3, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Andrew S LeveyJosef Coresh
Dec 3, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lesley A InkerAndrew S Levey
Dec 3, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Hiddo J Lambers HeerspinkLesley A Inker
Dec 3, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Tom GreeneAndrew S Levey
Dec 4, 2014·Diabetes Research and Clinical Practice·Hans-Henrik ParvingPeter Rossing
Jan 9, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Tobias F KröpelinHiddo J Lambers Heerspink
Mar 18, 2015·Lancet·Thaminda LiyanageVlado Perkovic

❮ Previous
Next ❯

Citations

Sep 24, 2016·Current Diabetes Reports·G Currie, C Delles
Oct 23, 2016·Journal of Diabetes and Its Complications·Emilie Hein ZobelPeter Rossing

❮ Previous
Next ❯

Methods Mentioned

BETA
urine collections

Clinical Trials Mentioned

NCT01858532

Software Mentioned

SONAR

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Richard A HoefieldJohn P New
Current Opinion in Nephrology and Hypertension
Paul KomendaNavdeep Tangri
Annals of Internal Medicine
Catherine M ClaseONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Rando
JAMA : the Journal of the American Medical Association
Stein I HallanChronic Kidney Disease Prognosis Consortium
© 2021 Meta ULC. All rights reserved